IMU (ASX) The CF33, Vaxinia and Oncarlytics Deal

Originally posted by zerotoleratfool ↑

Hi @mason14

Thank you for expressing your opinions pertaining to CF33. I don’t think anyone is disputing the scientific literature to date does not support CF33 overwhelmingly other than in animal models. Added to which the initial trial dosage rates for CF33 into late stage TNBC patients could never be expected to justify success, given the extent of cancer fighting against, and in all probability overcoming, the low initial dosage rates of CF33 applied. Whilst noone would argue the existing oncolytic virus market segment is miniscule in contrast to the broader cancer treatment market.

That said having met with Professor Yuman Fong, Saul Priceman M.D and Dr. Jakob Dupont, most if not all investors who attended the consecutive Imugene (non deal) roadshows were bouyed by the news that in the current Vaxinia Trial (i.e., treating up to 10 cancer lines in humans with solid tumours), the results are exhibiting “unequivocal signs of cancer killing in humans”. Now this claim made by Professor Yuman Fong of the City of Hope Cancer Research Facility was accentuated by his verbal acknowledgement that despite the need for higher dosage rates when administering through the IV format, Vaxinia was indeed effective in treating patients with solid tumours. By the way these were his words, not the words, opinions or views of uprampers (as you may suggest) on HC.

Recently we visualised signs of Imugene’s oncolytic viruses working behind the peritoneal (abdominal) cavity to reach out and destroy hard to treat solid tumours such as those in the liver and pancreas. Last year we were shown data supporting Imugene’s CF33 Oncarlytics arm wherein significant tumour killing was apparent. As you elude to much of this data is in xengraft models i.e., a tissue graft or organ transplant from a donor of a different species from the recipient. Therefore the risk associated with this data translating into humans is as you insinuate is a real one. However that said the data is pointing in the direction of success. For when leading cancer researchers, scientists and industry figures begin acknowledging the data they are seeing as “breakthogh therapy”, even the lay person must sit up and take notice.

I note your constant obsession with Imugene’s B cell treatment Her Vaxx, wherein you see it as under performing, all hype and no substance. To the contrary I believe the OSR data presented last June did indeed support the veracity of the drug, with gastric patients living close to 6 months longer having been dosed with Her Vaxx, over and above the standard of care. This may not constitute success in your mind, however I’m confident it does for those who either lived longer, or are still alive having been dosed with Her Vaxx, (or for that matter Imugene’s PD1 Vaxx). Once again as with Vaxinia, we are soon to see just how effective the drug is when combination results from the ongoing Her Vaxx Keytruda combination trial are revealed.

@mason14, keep in mind Vaxinia is a stronger, more potent parental virus than the strain of CF33 being trialled in late stage TNBC patients at the City of Hope. I would suggest you await the data from the current cohorts in that Vaxinia (MAST) trial before you start jumping to conclusions. Many of us on these threads are acutely aware of the need for preclinical data, particularly in IV format, to transition into “in human” results. Many of us are accepting of the fact that if these results do not eventuate the existing OV market sgement may continue to remain the poor cousin you refer to. Yet many if not all us have faith in the scientists appointed by Imugene and in the methodology behind their clinical trials. As the Vaxinia trial is now being conducted in up to 100 patients, across a broad cross section of solid tumour constituents, we are soon to realise a conclusion one way or another. Shall the outcome fall positively the way of Professor Fong, Dr Jakob Dupont, or Saul Priceman M,D, or shall it land in the lap of those who doubt the said science? Each to their own, but I’m happy to rest my hard earned in the lap of the humble world renowned cancer surgeon Professor Yuman Fong, and his colleagues nfrom the acclaimed City of Hope Cancer Research Facility.

Best of luck to all LTH’s

Opinions Only - Not Financial Advice

Expand

And the SP is less than a very junior miners IPO, that is a bit sad for a company doing so much good. Too much more good news and we will be down to points of a cent.

No.	Vol.	Price($)
48	13865872	1.2¢

No.

Vol.

Price($)

13865872

1.2¢

Price($)	Vol.	No.
1.3¢	7796628	25

Price($)

Vol.

No.

1.3¢

7796628

No.	Vol.	Price($)
52	14444109	0.012
47	11164018	0.011
58	17878374	0.010
20	4251934	0.009
11	5007499	0.008

No.

Vol.

Price($)

14444109

0.012

11164018

0.011

17878374

0.010

4251934

0.009

5007499

0.008

Price($)	Vol.	No.
0.013	7396628	24
0.014	13215227	31
0.015	12205138	34
0.016	6739357	29
0.017	12265156	16

Price($)

Vol.

No.

0.013

7396628

0.014

13215227

0.015

12205138

0.016

6739357

0.017

12265156

(20min delay)
Last 1.3¢		Change -0.002(10.7%)		Mkt cap ! $93.33M

Open	High	Low	Value	Volume
1.3¢	1.3¢	1.2¢	$164.6K	13.25M

The CF33, Vaxinia and Oncarlytics Deal, page-408

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

HotCopper Highlights for Week 25: 4DS Memory, Meeka & Sprott-citement

Week 25 Wrap: Fed & BoE pause rates ahead of RBA; Santos-ADNOC, Oz tax reforms

Monday's HotCopper trends: Trigg's Utah plans, Koonenberry assays| June 23

Ausgold closer to Katanning production hub dream with Critica licence buy

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

The CF33, Vaxinia and Oncarlytics Deal, page-408

Top Stories

Listen: HotCopper Wire Podcast 014 – Abu Dhabi wants to buy our 'true' oil and gas gem

HotCopper Highlights for Week 25: 4DS Memory, Meeka & Sprott-citement

Week 25 Wrap: Fed & BoE pause rates ahead of RBA; Santos-ADNOC, Oz tax reforms

Monday's HotCopper trends: Trigg's Utah plans, Koonenberry assays| June 23

Ausgold closer to Katanning production hub dream with Critica licence buy

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News